 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc. Nasdaq: TSHA, a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that Queens University in Ontario, Canada, received Clinical Trial Application CTA approval from Health Canada for its investigator-sponsored Phase 12 trial exploring TSHA-101, Tayshas inve 